文献速递肝病

磷脂酰乙醇与间接酒精生物标志物诊断MetALD与MASLD的头对头比较:一项前瞻性研究

Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-17

在374名超重或肥胖且MRI-PDFF≥5%的脂肪性肝病成人中,磷脂酰乙醇(PEth)诊断MetALD的AUROC为0.81(95%CI 0.73-0.89),约登切点为25 ng/mL,在头对头比较中优于所有既往间接酒精生物标志物(p<0.05)。

要点

  • 在脂肪性肝病成人中,PEth诊断MetALD的AUROC为0.81(95%CI 0.73-0.89),约登切点为25 ng/mL。
  • PEth在诊断MetALD方面优于天冬氨酸转氨酶/丙氨酸转氨酶比值、平均红细胞体积、γ-谷氨酰转移酶及ALD/NAFLD指数(p<0.05)。
  • PEth有潜力通过增强脂肪性肝病的亚分类来改变临床实践。

核心结论

  • PEth在区分MetALD与MASLD方面优于既往使用的非侵入性检测,并有潜力通过增强脂肪性肝病的亚分类来改变临床实践。

研究设计与样本

  • 这是对一项前瞻性研究进行的横断面分析,纳入374名居住在南加州、超重或肥胖且经MRI-PDFF≥5%定义为脂肪性肝病的成人。
  • 临床研究访视包括病史、生化和PEth检测、标准化验证问卷(包括AUDIT和LDH)、体格检查以及使用MRI-PDFF和MRE的先进影像学检查。

主要发现

  • 在374名脂肪性肝病成人中,MASLD、MetALD和ALD的患病率分别为90.1%、6.4%和3.5%。
  • PEth检测MetALD具有稳健的诊断准确性(AUROC 0.81,95%CI 0.73-0.89),约登切点为25 ng/mL。
  • 在头对头比较疗效分析中,PEth在诊断MetALD方面在统计学和临床上均优于所有既往使用的间接酒精生物标志物,包括天冬氨酸转氨酶/丙氨酸转氨酶比值、平均红细胞体积、γ-谷氨酰转移酶和ALD/NAFLD指数(p<0.05)。

关键数值与推荐

  • PEth检测MetALD的AUROC为0.81(95%CI 0.73-0.89),约登切点为25 ng/mL。
  • PEth在诊断MetALD方面优于天冬氨酸转氨酶/丙氨酸转氨酶比值、平均红细胞体积、γ-谷氨酰转移酶和ALD/NAFLD指数(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical and lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity and specificity. AIMS: To assess the diagnostic accuracy of PEth for differentiating metabolic dysfunction and alcohol-associated liver disease (MetALD) from metabolic dysfunction-associated steatotic liver disease (MASLD) in a large, population-based, prospective, multiethnic cohort of individuals with overweight or obesity. METHODS: This is a cross-sectional analysis of a prospective study including 374 adults with overweight or obesity residing in Southern California who had SLD as defined by MRI-PDFF ≥ 5%. The clinical research visit included medical history, biochemical and PEth testing, standardised validated questionnaires (including AUDIT and LDH), physical examination, and advanced imaging using MRI-PDFF and MRE. RESULTS: Among 374 adults with SLD, the prevalence of MASLD, MetALD, and ALD was 90.1%, 6.4%, and 3.5%, respectively. PEth had a robust diagnostic accuracy in the detection of MetALD (AUROC 0.81, 95%CI 0.73-0.89) and the Youden cut-off was 25 ng/mL. In head-to-head comparative efficacy analysis, PEth was both statistically and clinically superior to all previously used indirect alcohol biomarkers for diagnosing MetALD, including aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase, and ALD/NAFLD index (p < 0.05). CONCLUSIONS: PEth outperforms previously used non-invasive tests in differentiating MetALD from MASLD and has the potential to change clinical practice by enhancing the subclassification of SLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tavaglione F, Amangurbanova M, Yang AH, et al. Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study. Aliment Pharmacol Ther. 2025. PMID: 39825487. doi:10.1111/apt.18506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。